The Trump administration’s Centers for Medicare and Medicaid Services (CMS) has signaled that it will be revamping the ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Rep. Cory Mills (R-FL) sent a letter Tuesday to the chairman of Sichuan Kelun-Biotech Biopharmaceutical, Mr. Liu Gexin, "demanding answers to serious allegations regarding their ties to the Chinese C ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation ...

Mr. Kennedy appears to have most Republicans behind him as he seeks the job of health secretary, though he couldn’t escape ...

The Food and Drug Administration’s approval of low-risk tobacco pouches is welcome, but why did it delay for more than four ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Pharmaceutical companies have already raised the price of over 800 brand-name prescription drugs this year. Nearly all the ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...